US OptionsDetailed Quotes
SLRN241220C7500
- 0.31
- 0.000.00%
15min DelayClose Dec 13 16:00 ET
0.00High0.00Low
0.31Open0.31Pre Close0 Volume1.41K Open Interest7.50Strike Price0.00Turnover732.90%IV141.80%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.31Extrinsic Value100Contract SizeAmericanOptions Type0.2726Delta0.1244Gamma10.42Leverage Ratio-0.0958Theta0.0001Rho2.84Eff Leverage0.0012Vega
Acelyrin Stock Discussion
Sign in to post a comment
NOTE: I don’t have time to include those in my watchlist which didnt run. Just go back to it because those stocks will go usually after days or a week.
Sorry I am sleepy cant finish the list.
$Rigetti Computing (RGTI.US)$ PR today 12/10: Quantum Machines And Rigetti Computing Announces The Application Of AI To Automate The Calibration Of A Quantum Computer. Up after hours. SI 13.89%, 0 shares LTB✅
$SEALSQ Corp (LAES.US)$ PR 12/10: Partnership with IC’ALPS to ...
Sorry I am sleepy cant finish the list.
$Rigetti Computing (RGTI.US)$ PR today 12/10: Quantum Machines And Rigetti Computing Announces The Application Of AI To Automate The Calibration Of A Quantum Computer. Up after hours. SI 13.89%, 0 shares LTB✅
$SEALSQ Corp (LAES.US)$ PR 12/10: Partnership with IC’ALPS to ...
66
11
6
$Acelyrin (SLRN.US)$
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
ACELYRIN (Nasdaq: SLRN) announced that its Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis failed to meet its primary endpoint of showing statistically significant improvement in time to treatment failure versus placebo at 24 weeks. Secondary endpoints also did not achieve statistical significance.
Following these results and previous guidance, AC...
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
ACELYRIN (Nasdaq: SLRN) announced that its Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis failed to meet its primary endpoint of showing statistically significant improvement in time to treatment failure versus placebo at 24 weeks. Secondary endpoints also did not achieve statistical significance.
Following these results and previous guidance, AC...
1
24
$Acelyrin (SLRN.US)$ MT Newswires· 2 mins ago
Acelyrin (SLRN) said Thursday that the global late-stage trial of its treatment izokibep in patients with moderate-to-severe hidradenitis suppurativa yielded statistically significant improvement responses across multiple efficacy endpoints.
Acelyrin (SLRN) said Thursday that the global late-stage trial of its treatment izokibep in patients with moderate-to-severe hidradenitis suppurativa yielded statistically significant improvement responses across multiple efficacy endpoints.
1
$Acelyrin (SLRN.US)$
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery
Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes
LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused ...
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery
Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes
LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused ...
ACELYRIN, INC.: A New Horizon in Immunology.
ACELYRIN, INC. (Nasdaq: SLRN) is a late-stage clinical biopharmaceutical company devoted to accelerating the development and delivery of transformative medicines in the field of immunology. The company is making waves in the medical community with its promising treatments for various immune-related diseases. Founded with a mission to provide life-changing treatment options to patients, ...
ACELYRIN, INC. (Nasdaq: SLRN) is a late-stage clinical biopharmaceutical company devoted to accelerating the development and delivery of transformative medicines in the field of immunology. The company is making waves in the medical community with its promising treatments for various immune-related diseases. Founded with a mission to provide life-changing treatment options to patients, ...
2
No comment yet
AW138 : thank you sir, always appreciate your posts
DaTrader AW138 : I second that
WILLEE9ice : tons of thanks master, you have has done the jobs
Jenna Ragan : Thank you kindly
Tottigol10 : I can't understand unfortunately..any recommendations on where i can start to study and get more into it?
View more comments...